Lynovex

Lynovex® (NM001) is a first-in-class orphan drug candidate for cystic fibrosis.

Lynovex® In The News

Positive Top Line Data from the CARE CF 1 Clinical Study of Oral Lynovex in Cystic Fibrosis Exacerbations

Posted 10-Jul-2018

Cysteamine, an endogenous aminothiol, and cystamine, the disulfide product of oxidation, increase Pseudomonas aeruginosa sensitivity to reactive oxygen and nitrogen species and potentiate therapeutic antibiotics against bacterial infection.

Posted 03-Apr-2018

How Lynovex works to boost antibiotics in combatting Pseudomonas aeruginosa infection in cystic fibrosis

Posted 19-Mar-2018

NovaBiotics’ Lynovex receives Fast Track Designation for Cystic Fibrosis Exacerbations

Posted 12-Mar-2018

Enrolment reaches 50% in Lynovex CARE CF 1 trial

Posted 02-Nov-2017

More recent articles
Older articles

Upcoming Events

The NovaBiotics team will attend / present new Lynovex data at:

Research papers and posters

Lynovex Twitter Feeds & Webinars

Watch this space!